Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions Conference on Thursday, May 29, 2025 at 3:30 p.m. EDT.
Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Public markets primed for US IPO revival despite tariff uncertainty, NYSE President Martin says
By Arasu Kannagi Basil (Reuters) -Intercontinental Exchange-owned NYSE's President Lynn Martin said on Thursday that public markets were ready for well-prepared companies despite tariff unease as easing volatility was setting the stage for a rebound in U.S. IPO activity. Optimism that 2025 would finally be the year for a strong rebound in U.S. IPO market activity has recently been tempered by tariff-driven uncertainty, but the window seems to be opening up again after volatility eased and equities bounced back. "There's been this narrative in the market, particularly for the last two years. It's a bit false that companies can't go public," Martin said at the Piper Sandler Global Exchange & Trading Conference. The companies debuting at this time were public-market ready, she said, highlighting the successful listings of cybersecurity firm Rubrik and social media platform Reddit last year. "They were ready to go. They went, and they've done extraordinarily well," Martin said. Analysts say the IPO market could be in the early stages of a broader pickup, but that sustained stability was needed before the window opens fully. "We expect approximately one or two deals per week in June, ramping up a bit in July after Independence Day, and if all goes well, a full rebound in September, October after the summer lull," said Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs. NYSE TEXAS The impending launch of the Texas Stock Exchange, backed by Wall Street giants BlackRock and Citadel Securities, is set to heat up the competition in listings markets. The NYSE was following its playbook, talking to its customers about why more of them were moving to Texas, Martin said. NYSE Texas officially opened for business in March and has secured a handful of companies over the past few weeks - including Trump Media & Technology Group - as its "founding" members. "The conversations we're having are incredibly positive," Martin said, adding that NYSE Texas had another double-digit dual listing lined up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
an hour ago
- Miami Herald
GPOPlus+ Announces the Launch of Call Center Operations to Expand Direct B2B Sales
The new sales channel enhances nationwide reach and scalesrevenue, complementing its direct store delivery (DSD) distribution initialrevenuepotential of 10 seats is estimated to generate $50,000 to $100,000 per seat per month, totalling $500, up to 22 seats, generating $50,000 per month per seat, representing additional revenue of $1,100,000 monthly, or $13,200,000 annually. LAS VEGAS, NV / ACCESS Newswire / June 5, 2025 / GPO Plus, Inc.(OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model, today announced the launch of its new in-house call center operation based in Las Vegas, Nevada. This expansion marks a key milestone in GPOX's growth strategy, significantly broadening its ability to reach new retail customers and increase revenue across additional sales channels. The newly operational call center represents a highly scalable and cost-effective way to drive B2B sales to independent retailers, including smoke shops, vape shops, liquor stores, small grocers, and convenience stores that fall outside the traditional DSD footprint. This initiative works in tandem with the company's field teams, DISTRO+ Wholesale Portal, and regional hubs, forming a comprehensive multi-channel distribution strategy designed to accelerate nationwide growth. The team is starting with a well-curated lead database of over 70,000 retail accounts, focusing on selling GPOX's proven product lines, including its high-margin private-label SKUs. As previously announced, industry benchmarks indicate that $50,000-$100,000 in monthly sales can be achieved per seat. With operations now live, the call center is well-positioned to make meaningful contributions to top-line growth and drive additional market penetration, eliminating the need for physical delivery infrastructure. GPOX has hired an industry veteran and seasoned sales operations leader with extensive experience in call centers to lead the new team. The initial rollout includes up to 10 seats, with the infrastructure and lead volume in place to expand to 22 seats. The projected monthly revenue goal of $50,000 to $100,000 per seat, or $1.1 million to $2.2 million per month (expansion to 22 seats), and the corresponding annualized estimate of $13.2 million to $26.4 million are based on industry averages. "This is a high-impact revenue growth lever for GPOX that has moved quickly from concept to execution," said Brett H. Pojunis, CEO of GPOX. "We expect to have the first 10 seats filled by the end of July, and the expansion up to 22 seats by the end of fiscal Q2 (August to October, 2025). We've streamlined our operations, increased our margins, and now we're aggressively expanding. The call center allows us to rapidly scale into new geographies, deepen our retail penetration, and drive direct B2B sales. Our new manager brings exactly the leadership we need to maximize this opportunity." This initiative complements other recent activations, including the launch of the DISTRO+ Wholesale Portal, the opening of new ambient-temperature-controlled warehouses in Las Vegas and Lubbock, and the deployment of GPOX field teams to expand regional account penetration. For more information on GPOX's growth initiatives, visit Connect with us on social media to view live video updates, content, and general information about GPOX: About GPOPlus+ (GPOX)GPOX is an AI-powered Distributor revolutionizing the future of distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model. Our goal is clear and ambitious: "to build the largest nationwide DSD distribution company servicing gas stations, convenience stores, and beyond." Our technology-driven AI network, featuring strategically placed Regional Hubs and Mini Hubs, is designed to optimize efficiency and maximize reach. Central to our operations is our in-house AI technology platform, PRISM+. Designed to streamline the distribution process, PRISM+ supports efficient delivery, inventory management, data analytics, and overall operational excellence, enabling us to reliably and effectively meet the dynamic needs of our partners. Our mission is to consolidate the fragmented market segment managed by numerous regional vendors. Our dedication to excellence is evident in our product selection process, where we align offerings with consumer demand and partner with top-tier vendors and brands, ensuring our portfolio remains diverse and highly profitable. For more information, please visit Information about Forward-Looking StatementsThis press release contains "forward-looking statements" that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company's need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company's products, and other risks that are detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as "may," "will," "can" "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company's actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company's recent Securities and Exchange Commission filings, which are available at The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Company Contacts:GPOX Shareholder Success Team:Brett H. Pojunis, CEOEmail: ir@ Line: (4769) ### SOURCE: GPO Plus, Inc.
Yahoo
an hour ago
- Yahoo
Is this S&P 500 stock a once-in-a-decade passive income opportunity?
The S&P 500 has recovered from its volatile start to the year and is within touching distance of its record highs. At the same time, some quality shares are trading at exceptionally low prices. One example is Johnson & Johnson (NYSE:JNJ). As a rule, I stay away from pharmaceutical stocks, but I'm considering making a rare exception for this one. Johnson & Johnson has recently divested its consumer products business. The company now generates around 66% of its revenues from pharmaceuticals and 33% from medical devices. The main reason I generally stay away from stocks like this is I don't feel like I can evaluate them accurately. I'm not a medical professional and that means I can't confidently evaluate drug pipelines. That makes it hard to work out which businesses have the best prospects. And in fairness to me, it's not always straightforward even for people who do have specialist expertise in this sector. Johnson & Johnson does have some competitive strengths in this area – most notably its scale and its exceptional balance sheet. But there's something else that stands out to me about the company. A key part of what makes Johnson & Johnson unique is its culture. And this is set out in the 'Credo' – a document, which states that the company's priorities are, in order: Doctors, patients, nurses, and users of its products Employees Communities Shareholders In other words, focus on putting customers first and doing the right thing and the returns will follow. This ethical outlook is a key part of what has allowed the business to survive and thrive over decades. A lot of businesses have codes of conduct or ethical frameworks. But there's evidence that Johnson & Johnson's Credo means its culture is more entrenched than it is at other companies. The firm's reaction to the 1982 Tylenol crisis is now a well-known case study in ethical leadership. And it doesn't take specialist medical knowledge to appreciate the significance of this. Right now, shares in Johnson & Johnson come with a dividend yield of around 3.25%. That doesn't exactly jump out as a passive income opportunity, but it's the highest it has been in the last 10 years. This is a sign investors are unusually pessimistic about a stock they normally hold in high regard. And a key reason for this is the situation in the US at the moment. The situation is still developing, but potential risks include slower drug approval processes and price controls. Neither of these would be good for companies like Johnson & Johnson. The risk is real, but this might be the kind of opportunity that comes around once in a decade. Given the company's long-term strengths, I think it's worth taking seriously. I think Johnson & Johnson's biggest unique strength is its culture. Even if I'm wrong, there's clearly a lot to like about a company that has more than 50 years of consecutive dividend increases. Most of the time, the stock market appreciates the quality of the business. But it's unusually cheap at the moment and on that basis, it's certainly one to consider right now. The post Is this S&P 500 stock a once-in-a-decade passive income opportunity? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
